The Foghorn Vision
Our unique insight into one of the most fundamental systems of the human body empowers us to create different kinds of medicines – precision therapies with the potential to save lives.
Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression. These medicines are designed to modulate the chromatin regulatory system, which functions to orchestrate the genes our cells express — as well as when, where, and in what order.
Using our Gene Traffic Control® proprietary platform, we are rapidly advancing over 15 programs across a wide range of cancers — and aim to explore treatments for other diseases. Our two lead product candidates are currently in clinical development.
We are all impacted by disease in some way. Given our unique understanding of the chromatin regulatory system, we at Foghorn are inspired to transform the lives of people with a wide spectrum of diseases and make a real difference.
Headquartered in Cambridge, Mass., Foghorn Therapeutics has a leadership team with deep expertise in the discovery, development, and commercialization of leading-edge therapies – and a commitment to fostering an internal culture as unique and exciting as the treatments we are creating.